Patients requiring intensive care for COVID pneumonia have reduced exercise capacity and more frequent restrictive pulmonary function patterns in the early post-COVID period.

Among advanced therapies for Crohn's disease, adalimumab is linked to a higher chance of maintaining clinical remission.

Circulating endotrophin rises with fat gain and falls with fat loss, showing promise as a biomarker of body fat changes and a potential target for reducing obesity-linked health risks.

Recently approved nonhormonal options can help manage a range of symptoms, and potential new treatments are gaining momentum.

Etrasimod can be an effective and safe first-line advanced therapy option in patients with ulcerative colitis who escalate after conventional treatment failure.

Higher body fat percentage, rather than BMI, is associated with reduced sperm count and disrupted reproductive hormone levels in men.

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Exposure to wildfire-sourced fine particulate matter is linked to increased emergency department visits for migraine and other primary headache syndromes, a study shows.

Once-daily oral orforglipron offers an effective weight-loss option for adults aged 65 years or older with overweight or obesity, regardless of type 2 diabetes status.

In a 9-3 vote, an FDA advisory committee concluded that the available evidence does not support deramiocel's efficacy for treating cardiomyopathy in Duchenne muscular dystrophy.

Repeated episodes of weight loss and regain may be associated with a greater loss of muscle volume than keeping weight stable ...

A new analysis finds that drug and device manufacturers paid billions to physicians last year, yet thousands of records did ...